Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsBreaks – Organa Kannalytics Announces IBN’s HempWire as Official NewsWire of Southeastern Hemp & Medical Cannabis Convention

Organa Kannalytics has chosen InvestorBrandNetwork’s HempWire brand as an official media sponsor and official NewsWire of the Southeastern Hemp & Medical Cannabis Convention (“SHMC”). The three-day convention is scheduled for May 12–14, 2022, in Atlanta; the event will also be livestreamed. Organa Kannalytics is committed to bringing legitimacy to the hemp and medical cannabis industry by delivering science and education through its premier events. The SHMC expo features breakout sessions covering medical use and practices, business opportunities, the latest in scientific advancements, and local, state and national legislation affecting the cannabis and hemp industries; the event also offers invaluable networking opportunities. “We are pleased to be collaborating with both IBN and HempWire to maximize the success of the Southeastern Hemp & Medical Cannabis Convention,” said Organa Kannalytics founder and CEO Bridgett Graham in the press release. “IBN’s many brands and tools allow them to leverage communications solutions to heighten advance visibility of the SHMC, create a robust online presence, and strengthen the valuable connections between our team, executives in the space and industry enthusiasts. We are excited to host our 2022 event at the Cobb Galleria Centre in Atlanta. We believe IBN and HempWire can help us reach a broader audience, making it a better conference for all participants.”

To view the full press release, visit https://cnw.fm/6WcJJ

About Organa Kannalytics 

Organa Kannalytics is an innovative cannabis research company providing resources, discussion and scientific data to support cannabis-related health and wellness solutions. Through a coalition of cannabis-related business owners, legislators and scientists, the organization provides a wealth of scientifically based knowledge for consumers, families and medical facilities alike to make informed decisions about integrating cannabis and cannabis-based products into comprehensive health and wellness plans. The organization’s annual convention is an opportunity to learn about the business, legislative, medical and scientific aspects of the cannabis industry through workshops and panels facilitated by keynote speakers and also discusses current trends within the industry as well as obstacles that exists for cannabis users and growers. Organa Kannalytics’ mission is to provide scientifically based facts and information in an effort for consumers to make informed decisions in regard to creating healthy lifestyles by utilizing cannabis and cannabis-based products. For more information about the company, please visit www.OrganaKannalytics.com

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – CannabisNewsWire to Shine the Spotlight on the 2022 O’Cannabiz Conference and Expo

CannabisNewsWire (“CNW”), a specialized communications platform for the cannabis sector and one of the 50+ brands of IBN (“InvestorBrandNetwork”), today announced that it will again collaborate with the organizers of the O’Cannabiz International Conference & Expo. CNW is a platinum sponsor and will serve as the official newswire of the conference slated to take place June 1-3, 2022, at Toronto’s International Centre, Exhibit Hall 5. Working closely with O’Cannabiz, CNW will leverage IBN’s extensive array of corporate communications solutions to boost recognition for conference participants seeking to reach additional investors, journalists, businesses and consumers. CannabisNewsWire will provide amplified article syndication to its more than 5,000 strategic syndication partners and feature the conference on its dedicated events page. In addition, IBN’s affiliated brands, such as CBDWire and HempWire, will highlight the conference on their websites. “It’s always great to be working alongside O’Cannabiz’s team to help maximize awareness and media coverage for their annual event,” said IBN Communications Director Jonathan Keim. “O’Cannabiz has proven itself to be an ideal platform for presenting the latest innovations and investor opportunities emerging from the cannabis space. The 2022 O’Cannabiz Conference and Expo promises to be an outstanding networking event, with timely presentations and relevant sessions for every segment of the cannabis industry, and we’re looking forward to being part of it.”

To view the full press release, visit https://cnw.fm/AjJY4

About CannabisNewsWire

CannabisNewsWire (“CNW”), one of 50+ brands within IBN (“InvestorBrandNetwork”), is a specialized information service that (1) aggregates cannabis news; (2) provides CannabisNewsBreaks to quickly update investors in the space; (3) enhances corporate press releases; (4) provides social media distribution via IBN to millions of social media followers; and (5) delivers comprehensive corporate communication solutions. CNW is uniquely positioned in the cannabis market with a strong team of journalists and writers who can help private and public companies reach a wide audience of investors, consumers, journalists and the general public through our ever-growing dissemination network of 5,000+ key syndication outlets. CNW is bringing unparalleled visibility, recognition and content to the cannabis industry.

For more information, please visit www.CannabisNewsWire.com.

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer.

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Update on Human Nicotine Study NIC-H22-1

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced details of human nicotine study NIC-H22-1, which is expected to begin dosing this summer. According to the announcement, NIC-H22-1 is a minimum 36-person human pharmacokinetic (“pk”) randomized, double blinded, cross-over study to compare Lexaria’s DehydraTECH-nicotine pouch performance to that of existing leading brands currently sold in the U.S. such as ON! and Zyn. Lexaria hopes to evidence that processing purified nicotine with DehydraTECH leads to better oral-tissue absorption and reduced negative experiences compared to brands currently on the market. The study’s primary objective is data collection from blood samples that will evidence Tmax, Cmax and AUC. Secondary objectives of the study include extensive subjective evaluations related to throat burn, user experience and more. The design phase of NIC-H22-1 is complete, and test articles are currently being manufactured. Funding NIC-H22-1 with existing capital, the company is optimistic that this larger study will produce positive findings pursuant to those evidenced in its previous 2021 subjective human testing that utilized DehydraTECH-nicotine formulations demonstrating onset of initial nicotine effectiveness in as little as 1.5 to 4 minutes after an oral dose.

To view the full press release, visit https://cnw.fm/rt5cw

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”), and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 24 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) to Participate in Leading Cannabis Event

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, has announced that CEO Luis Merchan will be presenting at the upcoming Benzinga Cannabis Capital Conference. The event is scheduled for April 20–21, 2022, in Miami, Florida. Merchan’s presentation is slated to begin at 3:20 p.m. ET on April 20. In addition to Merchan’s presentation, members of Flora’s management team will be scheduling one-on-one investor meetings throughout the day. The Benzinga Cannabis Capital Conference gathers together more than 1,000 of the top movers and shakers in the cannabis industry and offers an invaluable opportunity for companies operating in the cannabis space to raise money, create partnerships and expand media visibility. The event agenda includes insightful keynote presentations, panel discussions, fireside chats, networking and company presentations as well as investor and celebrity appearances; this year’s event also features a larger exhibit floor and enhanced industry networking opportunities. “We’re looking forward to presenting at the Benzinga Cannabis Capital Conference and sharing valuable insights into our company and the industry as a whole with the attendees,” said Flora Growth CEO Luis Merchan in the press release. “Few events offer a lineup and networking opportunities as Benzinga does.”

To view the full press release, visit https://cnw.fm/SeBpS  

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands that delivers one of the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective farming practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. For more information about the company, please visit www.FloraGrowth.ca.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

InMed Pharmaceuticals Inc. (NASDAQ: INM) Gaining Advantage on Processing Rare Cannabinoids with the Help of Subsidiary Bay Medica

  • There is an urgent need for large-scale biosynthetic processing that preserves the purity and consistency of cannabinoids
  • Acquired by InMed in October 2021, Bay Medica is a private U.S. firm specializing in the manufacturing and commercialization of rare cannabinoids for the health and wellness sector
  • InMed has two cannabinol formulations currently in development for ocular and dermatological diseases – INM-088 (ocular for glaucoma) and INM-755 (dermatological cream for epidermolysis bullosa)

The global cannabis market increased exponentially after the pandemic hit, and is anticipated to continue its upward trend over the next few years. The market was valued at $20.47 billion in 2020, reporting a growth rate of 50.92% that year. The sector reached $28.66 billion in 2021 and is anticipated to hit $197.74 billion in 2028, expanding at a CAGR of 32.04% (https://cnw.fm/YYtTc). The market growth is paired with an increased demand for rare cannabinoids, with research showing that the biosynthesis of rare cannabinoids is projected to reach $25 billion in 2025 and up to $40 billion by 2040 (https://cnw.fm/B7SRh).

The problem faced by companies looking to work with rare cannabinoids on an industrial scale is the lack of efficient biosynthetic production methods that can ensure purity and consistency at high levels of production. Many companies find small-scale processing efficient for maintaining purity and consistency, but InMed Pharmaceuticals (NASDAQ: INM), which sees the potential of rare cannabinoids, is looking to scale up their production to commercial levels, and advanced biosynthetic production methods are necessary to ensure purity and consistency at such levels.

InMed is a clinical-stage company that is currently developing a pipeline of cannabinoid-based pharmaceutical drug candidates to treat several diseases with high, unmet medical needs. The company’s focus is on rare cannabinoids, many of which have variants that are not yet available in commercial-size quantities, such as cannabidivarin – CBDV and tetrahydrocannabivarin – THCV. 

The acquisition of Bay Medica in October 2021 has provided an advantage for InMed in the rare cannabinoid biosynthesis industry. Bay Medica is a private U.S. firm specializing in the manufacturing and commercialization of rare cannabinoids for the health and wellness sector and now operates as a subsidiary of InMed. Bay Medica is comprised of a team of key scientists and professionals from large-scale producers, which gives InMed the unique opportunity to use the technology to scale up the rare cannabinoid synthesis production.

In a January news release, Shane Johnson, SVP and General Manager of Bay Medica, said the company was delivering on its objective to launch additional rare cannabinoids in early 2022 in response to inbound demand. “By midyear, we expect to have at least four rare cannabinoids available for the health and wellness markets, positioning us as a leading large-scale supplier of high-quality rare cannabinoids in these sectors,” Johnson explained.

Evidence suggests that rare cannabinoids may produce exceptional therapeutic value. One of the rare cannabinoids that InMed has been working with is cannabinol (“CBN”). CBN is the active pharmaceutical ingredient (“API”) in two lead programs being pursued by the company for ocular and dermatological diseases. The company’s most advanced compound currently pursued is INM-755, a CBN topical cream under clinical development for treating epidermolysis bullosa (“EB”), a severe genetic skin disorder. InMed is also developing INM-088, an ocular CBN formulation researched for glaucoma treatment. INM-755 commenced a Phase 2 EB study across 13 sites in eight European countries in 2021.

For more information, visit the company’s website at www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX): A Review of Its Research Developments

  • Lexaria Bioscience, the global innovator behind DehydraTECH drug delivery technology, has continuously focused on research into its patented technology
  • The company has conducted both in vitro testing and in vivo animal and human testing to evaluate the ability of DehydraTECH to improve the delivery of various APIs (active pharmaceutical ingredients)
  • Lexaria has multiple other studies lined up aimed at building sufficient data to effect meaningful industry and/or regulatory progress and sustainable increases in valuation

As it moves toward national and international implementation and commercialization of its patented DehydraTECH(TM) drug delivery technology, Lexaria Bioscience (NASDAQ: LEXX) is aware of the need to continuously advance its understanding of the technology’s capabilities and potential applications. This informs the company’s long-held commitment to its applied research and development (“R&D”) programs, which are exclusively designed to “reduce future risks of both commercial and regulatory failure by identifying weaknesses as early as possible; and to enhance the likelihood of future commercial and regulatory success by thoroughly understanding strengths and weaknesses, also as early as possible” (https://cnw.fm/vY9V1).

Lexaria’s DehydraTECH technology combines a lipophilic active pharmaceutical ingredient (“API”) with a carrier particle, then it is dehydrated and finally rendered as a liquid or powder. Through the years, Lexaria has proven that DehydraTECH results in additional improvements, including speed of onset, increased brain absorption, increased bioavailability, and reduced drug administration costs, thanks to extensive research the company has continuously undertaken since 2015.

So far, the research journey has involved a series of controlled and well-designed in vitro pre-clinical testing and in vivo animal and human clinical studies, as well as all-encompassing molecular characterization investigations, which have been completed on APIs such as antiviral drugs, cannabinoids, nicotine and nicotine analogs, PDE5 inhibitors and non-steroidal anti-inflammatory drugs (“NSAIDs”). 

The company’s in vitro pre-clinical test, an absorption study, was performed to investigate unidirectional cannabidiol (“CBD”) permeability using a human epi-intestinal tissue model with multiple formulations in the presence of simulated intestinal fluid. According to Lexaria, the study evidenced a 325% and 499%, on average, in intestinal tissue permeability compared to two control groups.

Lexaria has also undertaken extensive clinical research starting in 2016. Multiple independent, well-designed, and controlled human studies conducted between 2016 and 2017, for example, corroborated the results from the in vitro studies. Since then, the company has undertaken numerous other studies evaluating the performance of various APIs processed using the DehydraTECH technology. For instance, Lexaria has investigated DehydraTECH-CBD as a potential treatment for hypertension and heart disease in multiple human studies, DehydraTECH-processed nicotine (animal study), and antivirals.  

“Performance of total bioabsorption (directly and indirectly through surrogate biomarkers), blood-brain-barrier delivery characteristics, rapidity of onset, consumer appeal, metabolite production (an indication of first-pass liver bypass), and quality of effectiveness have all been quantified,” Lexaria’s website says of the investigation parameters (https://cnw.fm/A2bcT).

Still, Lexaria is unrelenting in its pursuit of comprehensive datasets that would answer many questions the company expects to face from potential commercial partners or regulators and is, in fact, expanding its research. Last month, Lexaria kicked off an animal study to evaluate DehydraTECH-CBD as a potential treatment to inhibit seizure activity (https://cnw.fm/LLYWY), the first in a series of additional planned animal studies tentatively set to commence this year (https://cnw.fm/hzfZQ). Others include: 

  • HOR-A22-1: an animal study to evaluate DehydraTECH’s ability to improve the delivery characteristics of estrogen
  • DEM-A22-1: an efficacy study to investigate DehydraTECH-CBD with and without nicotine for the potential treatment of dementia
  • RHEUM-A22-1: an efficacy study to evaluate the ability of DehydraTECH-CBD to potentially impact the treatment of rheumatoid disease
  • DIAB-A22-1: an efficacy study to investigate DehydraTECH-CBD’s ability to potentially affect the treatment of diabetes

“DehydraTECH is not an EVOLUTION of existing technology – it is a REVOLUTIONARY new drug delivery platform. Expecting entire industries to change overnight to adopt a revolutionary process is not realistic: it takes time, evidence, and a lot of positive results to overcome industry inertia. We have long been hopeful that, before the end of 2022, we will have built sufficient data to effect meaningful industry and/or regulatory progress and sustainable increases in valuation,” Lexaria CEO Chris Bunka wrote in a recent letter to shareholders.

And with the planned and ongoing human and animal studies, Lexaria hopes to achieve precisely this.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Advanced Container Technologies Inc. (ACTX) Makes Mark at CannaCon Conference, Strengthens Foothold in Growing Market

  • The company exhibited at the premier event, held March 31–April 1, 2022
  • ACT has worked to strengthen its presence in the cannabis space
  • This strategic positioning comes as the global cannabis packaging market is projected to reach $297.51 billion by 2026

Advanced Container Technologies (OTC: ACTX) recently wrapped up a successful appearance at the CannaCon Conference, showcasing its new product line and strengthening brand awareness. The company exhibited at the premier event, held March 31–April 1, 2022, alongside Grassfire Distro, ACT’s exclusive packaging reseller (https://cnw.fm/sLimf).

Prior to the two-day event, Advanced Container Technologies CEO Doug Heldoorn noted that ACT had experienced “tremendous success” at last year’s CannaCon Conference. “We have an extensive line of new and exciting products that can help cannabis companies maximize profits throughout the ecosystem — from the cultivator to the retailer,” he stated. 

Since its participation in CannaCon last year, Advanced Container Technologies has worked to strengthen its presence in the cannabis space. Recognizing that safe, quality packaging in the sector is essential, ACT offers an impressive line of products, including an array of options for virtually every type of cannabis and hemp product, branding solutions, controlled environment cultivation systems, lighting, nutrients and a variety of other essential items.

Most recently, the company launched its Store ‘n Seal bags, a new line of premium-quality packaging (https://cnw.fm/NkH1N). The new commercial-grade bags are leak proof, odor proof and watertight, and are designed to store vegetables, lettuce, leafy greens and even cannabis safely. The bags, which feature thick 5ml plastic with a resealable zipper across the top, are available in two varieties: a silver bag with a see-through window and a black-out bag. Each bag holds up to two pounds of product.

This strategic positioning comes as the global cannabis packaging market is projected to reach $297.51 billion by 2026, with a CAGR of 22.59% (https://cnw.fm/0wr6N). ACT’s quality options aren’t going unnoticed; the company recently reported year-over-year revenues that show a 209% increase over the prior period, and company management expects that trend to continue. 

“We believe that we are in a stronger position than most of our competitors who are hampered by enormous operating expenses and dwindling growth rates,” says Heldoorn. “With our focus on remaining nimble and keeping costs and operating expenses as low as possible, we are in an excellent position to continue to grow rapidly outperform our competition in many key indicators.”

“As the cannabis market continues to become more competitive, it becomes even more important for companies to find new ways to increase profitability,” Heldoorn added. “Our unique product line can help companies grow brands, deepen customer loyalty, and increase profits.”

Advanced Container Technologies is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented, proprietary medical-grade plastic containers, known as the Medtainer(R), that store and grind pharmaceuticals, herbs, teas and other solids or liquids. 

For more information, visit the company’s website at www.AdvancedContainerTechnologies.com.

NOTE TO INVESTORS: The latest news and updates relating to ACTX are available in the company’s newsroom at https://cnw.fm/ACTX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — House Approves Bipartisan Cannabis Research Measure Days After Approving Federal Legalization Bill

Earlier this week, the House of Representatives passed a bipartisan cannabis research measure designed to streamline research on marijuana, partly by permitting researchers to access products sold in state-legal dispensaries. This vote comes days after the chamber approved the MORE Act , which would federally legalize marijuana. The research measure, dubbed the Medical Marijuana Research Act, was sponsored by Rep. Andy Harris and Rep. Earl Blumenauer and was approved by the legislators in a 343 to 75 vote.

Both the Senate and the House approved earlier versions of their separate marijuana research measures in 2020. However, none of these bills were advanced to the president’s desk by the end of the session. In a press release, Blumenauer stated that the marijuana laws in the country were broken, including the ones that dealt with the medical research of cannabis. He explained that America’s burgeoning marijuana industry operated without the benefit of a strong research program, noting that instead, the country was outsourcing research to Canada, the United Kingdom and Israel, to its disadvantage.

This measure would eliminate the barriers that scientists encounter when applying for and seeking approval to study marijuana. It would also establish clear deadlines on federal agencies to take action on researcher applications. The initiative would also make it easier for researchers to adjust their study protocols without seeking federal approval.

Frank Pallone, chair of the House Energy and Commerce Committee, stated that state-level reforms and approval of the federal marijuana legalization measure last week highlighted the need for more research on the effectiveness and safety of cannabis products. These types of products are being consumed by millions all over the United States, and increased research would be a crucial step toward understanding the negative and positive health effects of the products.

Rep. Morgan Griffith, who was a cosponsor of the marijuana research measure, voiced his support for the bill. Griffith noted that despite having varying views on broader cannabis reform, legislators had banded together to advocate for more studies on the use of marijuana products to treat medical conditions. After the vote on the research legislation, Blumenauer stated that he was ready to work with legislators in the Senate to reconcile differences between this measure and the Cannabidiol and Marihuana Research Expansion Act, which was approved by the Senate.

Advocates in favor of legalization commended the House measure, with NORML deputy director Paul Armentano stating that these regulatory changes were both necessary and long overdue. Once signed into law, the bill is sure to make the work of entities such as Cannabis Strategic Ventures Inc. (OTC: NUGS) a tad easier, especially on matters of conducting research and developing next-gen products.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Schumer Reaches Out to GOP Senators for Input on Upcoming Cannabis Legalization Bill

Senate Majority Leader Chuck Schumer has made his support for cannabis reform quite clear. Last year he revealed that he was working on a bill that would federally legalize cannabis and he has stated that he would act on cannabis legislation with or without President Joe Biden’s approval. However, efforts to pass some kind of marijuana legislation, whether it is widespread reform or cannabis banking, have been held back by the GOP.

Cannabis legalization is one of the many things Republicans and Democrats can’t seem to agree on. While a lot of Democrats believe that legalizing cannabis would be beneficial for the economy, millions of Americans looking for alternative medical options, and communities that were disproportionately harmed by the drug war, many Republicans are completely against legalizing cannabis.

With Schumer planning on introducing the Cannabis Administration & Opportunity Act (CAOA) to the Senate later this month, he has revealed that he and his colleagues are reaching out to GOP senators for their input on the bill. According to Schumer, he would like to see what the Republican senators would like to include in the bill before he files it near the end of April.

The legislation has been in the works for quite some time now, with the senate majority leader discussing plans to unveil it for longer than a year. Last February, Schumer said that he and his colleagues would be unveiling the Cannabis Administration & Opportunity Act before circulating a letter among lawmakers for input on the bill.

During a recent press briefing, Schumer said that he along with bill co-sponsors Senate Finance Committee Chairman Ron Wyden and Senator Cory Booker have been discussing the bill and are trying to reach out to lawmakers from the right for their input.

Schumer’s comments come just a few days after the House of Representatives passed the MORE Act for the second time. The legislation would end federal cannabis prohibition, launch a commercial cannabis market and try to alleviate the damage caused by the war on drugs. Unsurprisingly, most of the votes in favor of the bill came from the Democrats while only three Republicans approved the cannabis reform legislation.

As it stands, the GOP has repeatedly stood in the way of any federal cannabis reform that gets to the Senate as the left has a slim majority. If Schumer can get enough Republican senators on his side, Congress could finally legalize cannabis at the federal level after decades of prohibition, creating an environment that allows industry actors such as Advanced Container Technologies Inc. (OTC: ACTX) to offer value to people across the country.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Taking Diverse Product Portfolio to New Markets

Flora Growth Corp. (NASDAQ: FLGC) recently announced the successful import of Mambe CBD-containing food and beverage products into the United States from Colombia. The move capitalized on a new law signed by Colombian President Ivan Duque, which provides the necessary regulatory framework for cannabis product use and export. “Our team anticipated this regulatory update and has been laying the necessary foundation to expand this new supply chain pathway allowing Flora to quickly bring our diverse product portfolio and low-cost cannabis inputs to new high-growth international markets,” a recent article quotes Flora Growth CEO Luis Merchan as saying. Flora Growth also recently acquired JustCBD, which has an extensive network of more than 14,000 stores with over 300,000 customers, and, as a result, anticipates expanding Cosechemos-sourced non-psychoactive flower derivatives distribution during the coming months. The acquisition is also expected to boost JustCBD’s expansion from its U.S. base into international arenas. Additionally, Flora Growth announced the entry into an agreement by its Vessel brand with JustCBD-affiliated Speedy Distribution that will introduce Vessel’s vape and dry herb products into traditional smoke shop channels.

To view the full article, visit https://cnw.fm/lAPPZ

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands delivering the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. Visit www.FloraGrowth.ca or follow @floragrowthcorp on social media for more information.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.